PL3211077T3 - Sposoby oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje - Google Patents

Sposoby oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje

Info

Publication number
PL3211077T3
PL3211077T3 PL17155619.4T PL17155619T PL3211077T3 PL 3211077 T3 PL3211077 T3 PL 3211077T3 PL 17155619 T PL17155619 T PL 17155619T PL 3211077 T3 PL3211077 T3 PL 3211077T3
Authority
PL
Poland
Prior art keywords
proteins
compositions
methods
purifying recombinant
recombinant adamts13
Prior art date
Application number
PL17155619.4T
Other languages
English (en)
Inventor
Meinhard Hasslacher
Artur Mitterer
Christian Fiedler
Christa Mayer
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL3211077T3 publication Critical patent/PL3211077T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Sustainable Development (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Water Supply & Treatment (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL17155619.4T 2009-07-31 2010-08-02 Sposoby oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje PL3211077T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23030809P 2009-07-31 2009-07-31

Publications (1)

Publication Number Publication Date
PL3211077T3 true PL3211077T3 (pl) 2025-04-14

Family

ID=42588355

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10737917T PL2459715T3 (pl) 2009-07-31 2010-08-02 Sposób oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje
PL17155619.4T PL3211077T3 (pl) 2009-07-31 2010-08-02 Sposoby oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10737917T PL2459715T3 (pl) 2009-07-31 2010-08-02 Sposób oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje

Country Status (22)

Country Link
US (3) US8945895B2 (pl)
EP (3) EP2459715B1 (pl)
JP (6) JP5907869B2 (pl)
KR (7) KR20200146042A (pl)
CN (3) CN102482660A (pl)
AU (1) AU2010277491B2 (pl)
CA (2) CA2769362A1 (pl)
CO (1) CO6612194A2 (pl)
DK (1) DK2459715T3 (pl)
EA (3) EA034292B1 (pl)
ES (3) ES3039686T3 (pl)
HR (1) HRP20192303T1 (pl)
HU (1) HUE046909T2 (pl)
IN (1) IN2012DN00907A (pl)
LT (1) LT2459715T (pl)
MX (2) MX348178B (pl)
NZ (2) NZ597756A (pl)
PL (2) PL2459715T3 (pl)
PT (1) PT2459715T (pl)
SG (2) SG178175A1 (pl)
SI (1) SI2459715T1 (pl)
WO (1) WO2011012726A2 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101576219B1 (ko) 2007-03-14 2015-12-10 다케다 백신즈 인코포레이티드 바이러스 유사 입자 정제
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
JP5965927B2 (ja) * 2011-03-14 2016-08-10 キャタレント ファーマ ソリューションズ リミテッド ライアビリティ カンパニー デコリン組成物およびその使用
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9096648B2 (en) 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
MX347319B (es) * 2012-06-21 2017-04-21 Baxalta Inc Filtracion de virus de medio de cultivo celular.
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2943568B1 (en) * 2013-01-09 2019-11-20 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US8859252B1 (en) 2014-01-02 2014-10-14 Aerial Biopharma, Llc Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same
WO2015120056A1 (en) 2014-02-04 2015-08-13 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
KR20230079461A (ko) 2016-08-04 2023-06-07 다케다 파머수티컬 컴패니 리미티드 급성 폐 손상 및/또는 급성 호흡 곤란 증후군에서 혈관폐색 위기의 치료, 개선 및/또는 예방을 위한 adamts13의 용도
SG11202003793WA (en) 2017-10-30 2020-05-28 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
US20210024573A1 (en) * 2018-04-03 2021-01-28 Merck Patent Gmbh Cex chromatography media and low salt elution of target proteins from biopharmaceutical feeds
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
EP3947705A1 (en) * 2019-04-03 2022-02-09 Genzyme Corporation Continuous production of recombinant proteins
EP4037704B1 (en) 2019-10-04 2025-12-03 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
US11821000B2 (en) * 2020-11-10 2023-11-21 Dionex Corporation Method of separating viral vectors
EP4408876A1 (en) * 2021-09-30 2024-08-07 Ichnos Sciences SA Methods of inactivating viral contaminants with a mixture of solvent and detergent
TW202342522A (zh) 2022-03-07 2023-11-01 日商武田藥品工業股份有限公司 臨床人類ｉｇｇ產品之親和層析生產
KR20230159285A (ko) * 2022-05-10 2023-11-21 주식회사 녹십자 혈장 단백질의 동결 건조를 위한 신규한 액상 제형물
WO2023219378A1 (ko) * 2022-05-10 2023-11-16 주식회사 녹십자 혈장 단백질에 대한 신규한 액상 제형물
US20250334572A1 (en) * 2024-04-26 2025-10-30 Waters Technologies Corporation Host cell protein detection using lateral flow devices

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239854A (en) * 1978-04-24 1980-12-16 Sumitomo Chemical Company, Limited Enzyme-immobilization carriers and preparation thereof
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5283182A (en) * 1986-09-17 1994-02-01 Beecham Group Plc Preparation of immobilized hydantoinase stabilized with divalent metal ions
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
FR2681867B1 (fr) 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ATE194921T1 (de) 1992-03-02 2000-08-15 Bioeng Inc Verfahren zur inaktivierung von viren
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
GB9503750D0 (en) * 1995-02-24 1995-04-12 Common Services Agency Thrombin preparation
US5688912A (en) 1995-09-22 1997-11-18 Bayer Corporation Peptide ligands which bind to von willebrand factor
US5831003A (en) 1996-06-28 1998-11-03 Bayer Corporation Peptides which bind to prothrombin and thrombin
US5786458A (en) * 1996-06-28 1998-07-28 Bayer Corporation Selective stabilization of protein during viral inactivation
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
JP4707231B2 (ja) 1998-06-10 2011-06-22 スタテンズ セーラム インスティテュート マンナン結合レクチンを製造するための精製方法及びｍｂｌ医薬品
US6251860B1 (en) * 1998-07-07 2001-06-26 Suomen Punainen Risti Veripalvelu Pharmaceutical preparations
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
US6451978B2 (en) * 2000-01-21 2002-09-17 Biovitrum Ab Purification of antithrombin-III-α and β
IL136552A (en) 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
WO2002031163A1 (en) * 2000-10-11 2002-04-18 Kazusa Dna Research Institute Foundation Novel adamts family polypeptide and gene encoding the same
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
CN1230526C (zh) * 2001-02-27 2005-12-07 成都夸常科技有限公司 一种除去作为病毒灭活剂的有机溶剂和/或去污剂的方法
US7037658B2 (en) * 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
JP2003144154A (ja) * 2001-11-14 2003-05-20 Mitsubishi Pharma Corp 新規なａｄａｍｔｓファミリーポリペプチドおよびそれをコードする遺伝子
WO2003049117A2 (en) * 2001-12-05 2003-06-12 Cangene Corporation Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
PL374311A1 (pl) 2001-12-21 2005-10-03 Immunex Corporation Sposób oczyszczania protein
US20030133829A1 (en) * 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
GB0216002D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
JP3944586B2 (ja) * 2002-10-18 2007-07-11 国立循環器病センター総長 フォンビルブランド因子切断酵素の特異的基質および活性測定法
US20060134706A1 (en) 2003-07-09 2006-06-22 Michihiro Hide Atopic dermatitis inducer
CA2487673C (en) * 2003-12-02 2010-11-02 F. Hoffmann-La Roche Ag Improved method for the recombinant production and purification of protein kinases
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
WO2005099858A1 (en) * 2004-04-13 2005-10-27 Sangart, Inc. Methods and compositions for simultaneously isolating hemoglobin from red blood cells and inactivating viruses
DK1765866T3 (en) 2004-06-07 2014-03-24 Therapure Biopharma Inc ISOLATION OF plasma or serum protein
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7515392B2 (en) 2004-07-28 2009-04-07 Texas Instruments Incorporated High voltage circuits implemented using low voltage transistors
DE102004044419B4 (de) * 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
JP2006083044A (ja) 2004-09-17 2006-03-30 Hitachi Ltd ガラス部材
EP1838333A1 (en) * 2005-01-05 2007-10-03 Foundation For Fatal Rare Disease Pharmaceutically active antiviral peptides
US20060193966A1 (en) * 2005-02-28 2006-08-31 Shaowen Wu Multi-anion treated soy proteins and methods for preparation thereof
PL1902141T3 (pl) 2005-06-17 2012-12-31 Baxalta Inc Kompozycje o działaniu trombolitycznym zawierające ADAMTS13
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
US7506514B2 (en) 2005-06-30 2009-03-24 United Technologies Corporation Augmentor fuel conduit bushing
WO2007065691A2 (en) * 2005-12-07 2007-06-14 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
JP5067917B2 (ja) 2005-12-28 2012-11-07 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の分離精製方法
CA2642546A1 (en) 2006-02-16 2007-08-23 Mitsubishi Kagaku Iatron, Inc. Method for detection of condition in consciousness disorder patient and kit for the detection
US7468258B2 (en) 2006-03-07 2008-12-23 Wake Forest University Health Sciences Self-quenching homofluorophore compositions for detecting enzyme activity
WO2008057074A1 (en) * 2006-11-06 2008-05-15 Millipore Corporation Method of flow-through chromatography
JP5505853B2 (ja) 2007-02-13 2014-05-28 味の素株式会社 微酸性アルギニンを添加剤とするウイルス不活化法
US8685665B2 (en) * 2007-06-22 2014-04-01 The Chemo-Sero-Therapeutic Research Institute ADAMTS-13 mutant
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
EP2167526B1 (en) 2007-07-11 2011-03-30 Novo Nordisk A/S Purification of factor viii using a mixed-mode or multimodal resin
MX2010002249A (es) * 2007-08-31 2010-03-17 Amgen Inc Formulacion de proteina de estado solido.
US20090130714A1 (en) * 2007-09-24 2009-05-21 Reliance Life Sciences Pvt.Ltd. Process for purifying recombinanat tissue plasminogen activator (TPA)
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof

Also Published As

Publication number Publication date
US20230242897A1 (en) 2023-08-03
CN107267490A (zh) 2017-10-20
EP4299735B1 (en) 2025-05-21
AU2010277491A2 (en) 2012-06-21
CA2769362A1 (en) 2011-02-03
SG193855A1 (en) 2013-10-30
JP6216930B2 (ja) 2017-10-25
KR20190122272A (ko) 2019-10-29
US20110081700A1 (en) 2011-04-07
EP4299735A3 (en) 2024-04-24
HUE046909T2 (hu) 2020-04-28
NZ620988A (en) 2015-07-31
US12492390B2 (en) 2025-12-09
EP4299735A2 (en) 2024-01-03
EA201500952A1 (ru) 2016-05-31
EP3211077A1 (en) 2017-08-30
WO2011012726A3 (en) 2011-03-31
PT2459715T (pt) 2020-01-09
JP2022171925A (ja) 2022-11-11
JP2015147815A (ja) 2015-08-20
AU2010277491A1 (en) 2012-02-16
CA2916508A1 (en) 2011-02-03
EP2459715A2 (en) 2012-06-06
ES2763207T3 (es) 2020-05-27
DK2459715T3 (da) 2020-01-06
US8945895B2 (en) 2015-02-03
EA023783B1 (ru) 2016-07-29
SI2459715T1 (sl) 2020-01-31
SG178175A1 (en) 2012-03-29
US11661593B2 (en) 2023-05-30
JP2021004265A (ja) 2021-01-14
EA034292B1 (ru) 2020-01-24
KR101769634B1 (ko) 2017-08-18
JP2013500711A (ja) 2013-01-10
KR20200146042A (ko) 2020-12-31
AU2010277491B2 (en) 2015-12-17
JP2018203781A (ja) 2018-12-27
MX2012001263A (es) 2012-05-22
KR101883610B1 (ko) 2018-07-30
PL2459715T3 (pl) 2020-04-30
HRP20192303T1 (hr) 2020-10-02
EP2459715B1 (en) 2019-10-02
CN107988192A (zh) 2018-05-04
KR20180087463A (ko) 2018-08-01
LT2459715T (lt) 2020-01-10
MX348178B (es) 2017-05-29
EP3211077B1 (en) 2024-09-25
KR20120053013A (ko) 2012-05-24
NZ597756A (en) 2014-03-28
EA201992487A1 (ru) 2020-05-31
ES3039686T3 (en) 2025-10-23
JP2016222724A (ja) 2016-12-28
KR20220066435A (ko) 2022-05-24
CO6612194A2 (es) 2013-02-01
US20150104849A1 (en) 2015-04-16
BR112012002140A2 (pt) 2015-09-15
KR20230170815A (ko) 2023-12-19
IN2012DN00907A (pl) 2015-04-03
WO2011012726A2 (en) 2011-02-03
CN102482660A (zh) 2012-05-30
EA201270214A1 (ru) 2012-08-30
JP5907869B2 (ja) 2016-04-26
KR20170096061A (ko) 2017-08-23
ES3000382T3 (en) 2025-02-28

Similar Documents

Publication Publication Date Title
PL3211077T3 (pl) Sposoby oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje
EP2442829A4 (en) Structured viral peptide compositions and methods of use
IL209136A0 (en) Compositions of peptides and processes of preparation thereof
IL248880A0 (en) Preparations containing r-g-cysteic acid peptides and their uses
IL217280A0 (en) Compositions comprising combinations of phyto-cannabinoids and uses thereof
IL222961A0 (en) Novel dna-dinding proteins and uses thereof
LT3040424T (lt) Modifikuoti baltymai ir jų gavimo ir panaudojimo būdai
HUE059696T2 (hu) Triazolopirazin-származékok, készítményeik és alkalmazási eljárásuk
SG10201605794PA (en) Stable Pharmaceutical Composition And Methods Of Using Same
IL204183A (en) Preparations and Methods for Using Froisslet Peptides and Their Analogs
IL215762A0 (en) Mineral salt-sulfonic acid compositions and methods of use
ZA201207449B (en) Gene switch compositions and methods of use
EP2528932A4 (en) METHOD AND COMPOSITIONS FOR SEQUENCE-SPECIFIC PURIFICATION AND MULTIPLEX ANALYSIS OF NUCLEIC ACIDS
IL219470A0 (en) Compositions containing fractalknie-binding proteins and uses thereof
EP2231665A4 (en) NEW COMPOSITIONS AND METHODS OF USE
GB201005625D0 (en) Immunogenic proteins and compositions
GB201103423D0 (en) Immunogenic proteins and compositions
EP2395972A4 (en) PARTICULATE COMPOSITION AND METHOD FOR PRODUCING THE SAME
EP2519537A4 (en) CLEANING PROTEINS
EP2381950A4 (en) COMPOSITIONS AND METHOD FOR THEIR USE
HK1150065A (en) Compositions and methods of detecting post-stop peptides
AU2009905941A0 (en) Improved mineral based composition and methods of use